Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 6/20 | 0.49 |
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | DRD1 | P21728 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SORD | Q00796 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23964209 | 0.81 | DRD3 (0.49) | DRD3DRD2DRD4DRD1PIK3CB | |
| SCHEMBL23964258 | 0.80 | DRD3 (0.50) | DRD3DRD2DRD4DRD1PIK3CB | |
| SCHEMBL23964127 | 0.79 | DRD3 (0.49) | DRD3DRD2DRD4DRD1KCNH2 | |
| SCHEMBL23964351 | 0.78 | DRD4 (0.49) | DRD3DRD2DRD4DRD1KCNH2 | |
| SCHEMBL23964128 | 0.77 | DRD3 (0.45) | DRD3DRD2DRD4DRD1PIK3CB | |
| SCHEMBL23964199 | 0.76 | DRD3 (0.44) | DRD3DRD2DRD4DRD1PIK3CB | |
| SCHEMBL23964126 | 0.76 | DRD3 (0.51) | DRD3DRD2DRD4DRD1KCNH2 | |
| SCHEMBL23964197 | 0.75 | DRD3 (0.47) | DRD3DRD2DRD4DRD1PIK3CB | |
| SCHEMBL23964195 | 0.74 | DRD3 (0.60) | DRD3DRD2DRD4DRD1NPC1 | |
| SCHEMBL30297594 | 0.74 | LMNA (0.46) | DRD3DRD2DRD4DRD1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2021216665-A9 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021216665-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | DRD3 4747/4885DRD2 4780/4885DRD4 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.